Hims & Hers Launches GLP-1 Weight-Loss Drugs in Australia Following Acquisition

Hims & Hers Health Inc. (NYSE:HIMS) announced it has launched branded GLP-1 weight-loss medications and other men's health treatments in Australia. The expansion leverages the company's recently acquired Pilot platform, a men's telehealth brand based in Sydney.

Strategic Expansion Down Under

The move follows the telehealth firm's purchase of Australian digital health company Eucalyptus earlier in 2026. Through the established Pilot brand, Hims & Hers will now offer a range of treatments including sexual health medications and cholesterol therapies alongside the popular weight-loss drugs.

"Combining Pilot’s deep local knowledge with Hims’ global platform gives us a meaningful opportunity to help even more Australians access better, more comprehensive weight-loss care," said Tim Doyle, the former Eucalyptus CEO who now serves as a senior vice president at Hims & Hers. The company also plans to launch its women’s health services in Australia later in 2026 under the Juniper brand, which was also part of the Eucalyptus acquisition.

Ad

Financial Implications and Outlook

This international push is a core component of the company's strategy to reach $6.5 billion in revenue by 2030. While international business has successfully increased subscriptions and boosted monthly revenue per subscriber by 21% year-over-year, it has also put pressure on profitability.

During its second-quarter earnings call, Hims & Hers management noted that it expects gross margins to remain below historical levels as it accelerates its international offerings. This highlights the significant investment required for global expansion, which can temporarily impact profitability metrics even as it drives top-line growth.